garetosmab   Click here for help

GtoPdb Ligand ID: 14668

Synonyms: garetosmab-grts | Pasatru® | REGN-2477 | REGN2477
Approved drug
garetosmab is an approved drug
Compound class: Antibody
Comment: Garetosmab (REGN2477) is a fully human anti-activin A (INHBA) monoclonal antibody [4]. The antibody blocks signaling of activins containing the inhibin βα subunit (i.e., activins A, AB, and AC). Peptide sequence matches in a patent search suggests that garetosmab is antibody H4H10446P2 in Regeneron Pharmaceuticals' patent US9718881B2 [3].
No information available.
Summary of Clinical Use Click here for help
Garetosmab (REGN2477) was progressed as a clinical candidate for the treatment of fibrodysplasia ossificans progressiva (FOP) [1]. First approval was granted by the US FDA in August 2026, to reduce new heterotopic ossification and flare-ups in patients with FOP.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05394116 A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) Phase 3 Interventional Regeneron Pharmaceuticals
NCT07559513 A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) Phase 3 Interventional Regeneron Pharmaceuticals
NCT03188666 A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva Phase 2 Interventional Regeneron Pharmaceuticals 2